Minimizing the progression of kidney disease. Introduction.
Flack
J M
JM
Department of Internal Medicine, Wayne State University, Detroit, Michigan.
D000804:Angiotensin II / Q000502:physiology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000503:physiopathology; D018450:Disease Progression; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000517:prevention & control; D007674:Kidney Diseases / Q000188:drug therapy / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000517:prevention & control*; D010347:Patient Care Planning; D012084:Renin-Angiotensin System / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D000804:Angiotensin II